Percheron Therapeutics Ltd News

Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%

Percheron Therapeutics (ASX:PER) completed the enrollment of 48 non-ambulant boys for its phase 2b trial investigating the use of the ATL1102 medication to treat Duchenne muscular dystrophy, according

MT NewswiresMay 28 23:02 ET

Here's Why We're Watching Percheron Therapeutics' (ASX:PER) Cash Burn Situation

Yahoo FinanceMay 23 20:25 ET

WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102

Percheron Therapeutics (ASX:PER) said that the World Health Organization chose avicursen as the proposed international nonproprietary name for its investigational drug candidate, ATL1102, according to

MT NewswiresMay 5 23:33 ET

Shareholders Have Faith in Loss-making Percheron Therapeutics (ASX:PER) as Stock Climbs 26% in Past Week, Taking Five-year Gain to 142%

Yahoo FinanceFeb 29 17:51 ET

Percheron Therapeutics Target Price Cut 10% to A$0.27/Share by Wilsons>PER.AU

Percheron Therapeutics Target Price Cut 10% to A$0.27/Share by Wilsons>PER.AU

Dow JonesJan 31 16:12 ET